SREBF2 and metabolic dysfunction-associated steatotic liver disease: In the present study, we treated NAFLD rats with CHLZT and then analyzed their blood’s biochemical parameters to determine how the affects produced by CHLZT might be related to AMPK, PPAR-γ, SREBP2, and signaling.